CIK 0001714899 · Large accelerated filer
Denali Therapeutics Inc.
Sign in to watch- Ticker
- DNLI
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 463872213
- Phone
- (650) 866-8547
- Business address
- 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- SC 13G Stake Amended Statement of Ownership
- 4 Open-market sale COFO and Secretary sold 2,272 shares at $22.89 ($52,006)
- 4 Open-market sale Chief Medical Officer sold 2,337 shares at $22.89 ($53,494)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Planned sale Director sold 30,688 shares at an average $22.11 ($678,660)
- 4 Planned sale Director sold 3,080 shares at an average $22.14 ($68,204)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 4 Planned sale Director sold 1,458 shares at $21.73 ($31,682)
- 144 Insider Sale of Securities
- 4 Grant or award Director acquired 5,967 shares (grant or award)
- 4 Grant or award Director acquired 5,967 shares (grant or award)
- 4 Grant or award Director acquired 5,967 shares (grant or award)
- 4 Grant or award Director acquired 5,967 shares (grant or award)
- 4 Grant or award Director acquired 5,967 shares (grant or award)
Page 9 of 40 · 789 filings